Hormone Receptor-positive Breast Cancer
📧 Sign up to get email alerts when something new happens for Hormone Receptor-positive Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-11-04Clinical Trial Update: A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer [Phase 2]
A Phase 2 clinical trial assessing SHR-A1811 as neoadjuvant therapy for HR-positive, HER2-low breast cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2024-10-01Clinical Trial Update: Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)
This clinical trial update describes a retrospective observational study evaluating the safety and toxicity management of abemaciclib in com…
-
CLINICAL_TRIALS research · 2024-08-12Clinical Trial Update: Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer
This document notes that a clinical trial evaluating treatment for ESR1-mutated HR+/HER2- advanced breast cancer in Chinese patients is curr…
-
CLINICAL_TRIALS research · 2024-08-01Clinical Trial Update: Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative [Phase 3]
Phase III trial status update for SHR6390 in combination with placebo and endocrine therapy as adjuvant treatment for hormone receptor-posit…
-
CLINICAL_TRIALS trial_result · 2024-07-31Clinical Trial Update: A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer [Phase 1]
This Phase 1 dose-escalation trial of taselisib (GDC-0032) in locally advanced or metastatic solid tumors or Non-Hodgkin lymphoma, including…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-07-30Clinical Trial Update: Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer [Phase 1]
Phase 1 study evaluating the addition of copanlisib to fulvestrant and abemaciclib for metastatic breast cancer, with results posted in 2024…
-
CLINICAL_TRIALS trial_result · 2024-07-29Clinical Trial Update: Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer [Phase 2]
A Phase 2 trial evaluating palbociclib in combination with tamoxifen as first-line therapy for metastatic hormone receptor-positive, HER2-ne…
-
CLINICAL_TRIALS research · 2024-07-10Clinical Trial Update: Efficacy and Safety of Dalpiciclib Plus Toremifene in the Treatment of Advanced First-line HR Positive and HER2 Negative Breast Cancer: a Multicenter, Single Arm, Exploratory Phase II Clinical Study [Phase 2]
A multicenter, single-arm Phase II trial assessing dalpiciclib in combination with toremifene for first-line advanced hormone receptor-posit…
-
CLINICAL_TRIALS research · 2024-06-24Clinical Trial Update: To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating Adebrelimab in combination with chemotherapy after HIFU-based neoadjuvant therapy for hormone receptor-pos…
-
CLINICAL_TRIALS research · 2024-06-18Clinical Trial Update: Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL Study
Real-world study from Portugal (REVEAL) reports on treatment patterns with cyclin-dependent kinase inhibitors in advanced breast cancer; the…
-
CLINICAL_TRIALS research · 2024-06-07Clinical Trial Update: Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer [Phase 3]
This is a Phase 3 clinical trial update evaluating apatinib in combination with a CDK4/6 inhibitor as first-line therapy for HR+/HER2- breas…
-
FDA approval · 2024-04-30FDA Approved: EVEROLIMUS — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Everolimus submitted by Hikma Pharmaceuticals USA Inc. This action updates approved labeling…
-
CLINICAL_TRIALS trial_result · 2024-04-23Clinical Trial Update: Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients [Phase 2]
Phase 2 trial update evaluating a higher dose of preoperative taMOxifen in premenopausal women with hormone receptor-positive breast cancer.
-
CLINICAL_TRIALS trial_result · 2024-04-05Clinical Trial Update: Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer [Phase 2]
A Phase 2 trial evaluated two ribociclib dose levels in combination with aromatase inhibitors for HR-positive, HER2-negative advanced breast…
-
CLINICAL_TRIALS trial_result · 2023-12-12Clinical Trial Update: Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant [Phase 2]
Phase 2 trial evaluating safety and efficacy of adding dapagliflozin to extended-release metformin versus metformin XR alone in HR+, HER2-, …
-
CLINICAL_TRIALS trial_result · 2023-06-15Clinical Trial Update: TCb vs EC-T in High Risk ER+/HER2- Breast Cancer [Phase 3]
Phase 3 clinical trial update comparing TCb versus EC-T in high-risk ER+/HER2- breast cancer; currently recruiting.
-
CLINICAL_TRIALS trial_result · 2023-06-12Clinical Trial Update: Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer [Phase 3]
Phase 3 trial evaluating docetaxel, carboplatin, trastuzumab, and pertuzumab with or without estrogen deprivation in hormone receptor-positi…
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients [Phase 4]
Phase 4 clinical trial updating on ribociclib efficacy and resistance patterns in advanced breast cancer.
-
CLINICAL_TRIALS trial_result · 2022-08-29Clinical Trial Update: Palbociclib With Everolimus + Exemestane In BC [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating palbociclib in combination with everolimus and exemestane in HER2-negative, HR-positive breast cancer …
-
FDA approval · 2021-12-10FDA Approved: KISQALI FEMARA CO-PACK — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application to approve a co-packaged formulation of KISQALI (ribociclib) with FEMARA (letrozole), enabling their…
-
CLINICAL_TRIALS trial_result · 2021-11-16Clinical Trial Update: Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic [Phase 3]
Phase 3 trial evaluating exemestane with or without entinostat in recurrent hormone receptor-positive, HER2-negative breast cancer that is l…
-
CLINICAL_TRIALS trial_result · 2020-07-07Clinical Trial Update: Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors [Phase 2]
A Phase 2 clinical trial evaluating neoadjuvant response-guided treatment for slowly proliferating hormone receptor positive breast tumors.
-
FDA approval · 2020-07-06FDA Approved: KISQALI FEMARA CO-PACK — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for a Kisqali-Femara co-pack, combining ribociclib and letrozole in a single co-pack managed by Nova…
-
CLINICAL_TRIALS trial_result · 2019-04-10Clinical Trial Update: Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC [Phase 2]
A Phase 2 trial evaluating pyrotinib in combination with trastuzumab and AI for first-line treatment of HER2-positive, hormone receptor-posi…
-
FDA approval · 2019-02-13FDA Approved: KISQALI FEMARA CO-PACK — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application to co-pack Kisqali (ribociclib) with Femara (letrozole), enabling a fixed-dose co-pack for postmenop…